Kulvinder Kochar Kaur¹*, Gautam Allahbadia² and Mandeep Singh³

¹Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
²Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
³Consultant Neurologist, Swami Satyan and Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: November 22, 2021; Published: December 31, 2021

Abstract

India possesses a greater tuberculosis (TB) load in contrast to any other country, that accounts for a calculated 25% of the global load. Drug resistant tuberculosis (DR-TB) is a biggest public health difficulty in India. Massive alterations In the drug regimens is the requirements, for patients with DR-TB, that are mostly correlated with poor sticking to the treatment in addition to less than optimal treatment results in contrast to the drug sensitive tuberculosis. This hurdle of tackling DR-TB is key with regards to India, since India aids In greater than27% of global DR-TB patients. In the last few decades India has, become energetic with its fight against tuberculosis, with an execution of a revised National Strategic Plan (NSP) with the aim of eradication of TB by 2025. Nevertheless, for accomplishment of this aspiring objective, the requirement for India is to take a multistep strategy with regards to the DR-TB management. Inspite of consistent actions done via the National Tuberculosis Elimination Programme, considerable hurdles are faced by India in the context of DR-TB –care, specifically in peripheral, apart from resource restricted endemic areas. Here certain biggest short comings that are correlated with the escalation of the DR-TB epidemic in India as well as their influence.

Keywords: Tuberculosis; Epidemic; India; DR-TB; Diagnostics; MDR-TB Management

References

1. World Health Organization. “Global Tuberculosis report” (2020).
2. Central TB Division, Ministry of Health and Family Welfare. “India TB report 2020”: National Tuberculosis Elimination Programme annual report (2020).
3. Chatterjee Setal. “Drug resistant Tuberculosis: is India ready for the challenge?” Global Health 3 (2018): e000971.
4. Husai AA., et al. “Controlling the drug resistant tuberculosis epidemic in India: challenges and implications”. Epidemiology and Health 43 (2021): e2021022.
5. Chaudhari AD. “Recent changes in Guidelines on Programmatic management of drug resistant Tuberculosis in India 2019: a paradigm shift in Tuberculosis Control”. The Journal of Association of Chest Physicians 8 (2020): 53-63.
6. World Health Organization: “Standards for TB care in India” (2014).
7. Ministry of Health and Family Welfare, government of India. “Report of first National anti-tuberculosis drug resistance survey India” (2014).
8. World Health Organization: Definitions and reporting frame works for tuberculosis 2013 revision (2014).
9. Arinaminpathy N., et al. “The number of privately treated tuberculosis cases in India: an estimation from drug sales data”. The Lancet Infectious Diseases 16 (2016): 1255-1260.
10. Yellappa V., et al. “Patients pathway to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study from a south Indian district”. BMC Public Health 17 (2017): 635.
11. Siddaiah A., et al. “Tuberculosis notification in a private tertiary care teaching hospital in SouthIndia: a mixed method study”. BMJ Open 9 (2019): e023910.
12. Yadavar S. “More than half of Indias drug resistant tb cases remain undetected”. India Spend (2019).
13. Prasad R., et al. “Multi drug resistant tuberculosis/ rifampicin resistant tuberculosis: principles of management”. Lung India 35 (2018): 78-81.
14. Schito M., et al. “Perspectives on advances, diagnostics, drugs and vaccines”. Clinical Infectious Diseases 3 (2015): S102-S118.
15. Sharma K., et al. “Xpert MTB/RIF Ultra for the diagnosis of tuberculous meningitis: a diagnostic accuracy study from India”. Tuberculosis (Edinburgh, Scotland) 125 (2020): 101990.
16. Dorman SE., et al. “Xpert MTB/RIF Ultra for detection of Mycobacterium Tuberculosis and rifampicin resistance: a prospective multicenter diagnostic accuracy study”. The Lancet Infectious Diseases 18 (2018): 76-84.
17. World Health Organization: Tuberculosis diagnostics: molecular line probe assay for the detection of resistance to second line anti TB drugs (SL-LPA) (2020).
18. World Health Organization: “The use of Molecular line probe assay for the detection of resistance to isoniazid and rifampicin” (2016).
19. Lee DJ., et al. “Rapid, point of care diagnostics of tuberculous with novel True Nat assay:cost effectiveness analysis for India private sector”. PLoS ONE 14 (2019): 0218890.
20. Indian Council of Medical Research. “World Health Organization endorses True Nat tests for initial diagnosis of tuberculosis and detection of resistance to rifampicin” (2020).
21. Cao Y., et al. “Xpert MTB /XDR: a 10color reflex assay suitable for point of care settings to detect isoniazid fluoroquinolones, and second line injectable drug resistance directly from Mycobacterium Tuberculosis positive sputum”. Journal of Clinical Microbiology 59 (2021): e2314-e2320.
22. Pinto L and Menzies D. “Treatment drug resistant tuberculous”. Infectious Disease Resistance 4 (2011): 129-135.
23. Gualano G., et al. “New anti-tuberculous drugs: from Clinical trial to Programmatic use”. Infectious Disease Reports 8 (2016): 6569.
24. World Health Organization. WHO consolidation guidelines on drug resistant tuberculosis treatment (2016).
25. Sharma SK., et al. “What is new in the WHO consolidation guidelines on drug resistant tuberculosis treatment?” Indian Journal of Medical Research 149 (2019): 309-312.
26. Saravu K and Pal M. “Drug resistance tuberculous: progress towards shorter and safer regimens”. Lung India 36 (2019): 373-375.
27. Muller patan JB., et al. “Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India”. Indian Journal of Tuberculosis 66 (2019): 87-91.
28. Gupta R. “Spoligotyping, phenotypic and genotypic characterization of kat G, rpo B gene of M. Tuberculosis isolates from Sahariya tribe of Madhya Pradesh”. Journal of Infection and Public Health 2 (2019): 395-402.
29. Udwadia ZF., et al. “Few eligible for the newly recommended short course MDR- TB regimen at a large Mumbai private clinic”. BMC Infectious Diseases 19 (2019): 94.
30. AlGhafli H., et al. “Drug resistant profiling TB and transmission dynamics of multi drug resistant Mycobacterium Tuberculosis in Saudi Arabia revealed by whole-genome sequencing”. Infectious Disease Resistance 11 (2018): 2219-2229.
31. Dookie N., et al. “Whole-genome sequencing to guide the selection of treatment for drug resistant tuberculosis”. Antimicrobial Agents and Chemotherapy 62 (2018): e00574-e005718.
32. Kulvinder Kochar Kaur., et al. “Advances in diagnosis and Management of female Genital Tuberculosis-A Comprehensive Review". Acta Scientific Microbiology6 (2019): 1-8.

Citation

Citation: Kulvinder Kochar Kaur., et al. “Regulation of the Hurdles in Addition to the Obstacles Associated With the Eradication of Drug Resistant Tuberculosis Epidemic in India - Stress on the: National Tuberculosis Elimination Programme". Acta Scientific Microbiology 5.1 (2022): 107-115.

Copyright

Copyright: © 2022 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.